

It's easy for your patients to get started on the FreeStyle Libre 2 system if they have Medicare*^{1,2}



CMS has provided greater flexibility during the COVID-19 Public Health Emergency (PHE) to allow more diabetic patients to monitor their glucose and adjust insulin doses from home by using a therapeutic CGM*^{1,2}.

PARTICIPATING SUPPLIERS TO HELP GET YOUR PATIENTS STARTED ON THE FREESTYLE LIBRE 2 SYSTEM:

[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]
[Supplier Name]	[Phone Number]	[Supplier Name]	[Phone Number]

Last Updated [XX/XXXX].

Providers listed above include all DME suppliers who have contracted with ADC to acquire FreeStyle Libre family of products directly as of the "Last Updated" date who have represented to ADC they intend to recognize the flexibility provided by CMS. For a complete listing of DME suppliers contracted directly with ADC go to [URL].

FreeStyle Libre family of products may be available through other suppliers not listed who acquire these products indirectly.

This listing of participating suppliers are in alphabetical order and ADC has no preference on the supplier selected from the list. All DME suppliers who have contracted with ADC to acquire FreeStyle Libre family of products directly were eligible to be listed if they indicated they will supply CGM according to the CMS PHE guidelines*^{1,2}.



*As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer's providers are ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.

References: 1. On May 8, 2020, CMS published a second interim final rule with comment, CMS-5531-IFC, that expanded the non-enforcement of clinical indications of coverage to therapeutic continuous glucose monitors (CGMs). This IFC also clarified that statutory reasonable and necessary statutory requirements are not being waived due to the PHE. <https://www.govinfo.gov/content/pkg/FR-2020-05-08/pdf/2020-09608.pdf>. 2. CMS Issues Interim Final Rules with Comment (CMS-1744-IFC & CMS-5531-IFC) – COVID-19 Public Health Emergency – Revised June 29, 2020, <https://www.cgsmedicare.com/jc/pubs/news/2020/06/cope17942.html>.

See Important Safety Information on reverse.



**MORE
PATIENTS
CAN
DO IT
WITHOUT
FINGERSTICKS***

Learn more at [\[Pharmacy.FreeStyleLibre.us\]](https://Pharmacy.FreeStyleLibre.us)

or

Contact our Customer Care Team for help finding a supplier,

 **1-844-330-5535**

Available 7 days a week, 8 AM to 8 PM Eastern Time; excluding Holidays.



life. to the fullest.®

Abbott

Product images are for illustrative purposes only. Not actual patient data.

*Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

Important Safety Information

Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

©2022 Abbott. ADC-26373 v3.0 01/22